OncoLens Resources

Mar 01, 2021 | Education

NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients

Mar 01, 2021 | Education

Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result

Mar 01, 2021 | Education

NSCLC Patient and Adjuvant Chemotherapy

Feb 01, 2021 | Education

Patient with Possible Synchronous Early-stage NSCLC and Different DetermaRx Results

Feb 01, 2021 | Education

Patient with NSCLC Who Recurred within a Year

Feb 01, 2021 | Education

Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion

Feb 01, 2021 | Education

Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy

Jan 14, 2021 | News and Events

Fast-Growing Oncology Startup OncoLens Secures $7.25 Million Series A Funding

Dec 11, 2020 | Case Studies

Best Practices: Building the Future of Multidisciplinary Cancer Care

Dec 01, 2020 | Education

MTC: Patient with Stomach Cancer and KIT exon 11 and ATM Mutations

Dec 01, 2020 | Education

Patient with Prostate Cancer and CDK12 and TP53 Mutations

Dec 01, 2020 | Education

MTB Discussion for Patients with KIT and CDK12 Mutations

Nov 30, 2020 | News and Events

Karmanos Cancer Institute to Implement OncoLens Multidisciplinary Cancer Treatment Planning Software Solution

Nov 04, 2020 | News and Events

Four Factors Affecting the Post-COVID Cancer Care Landscape

Aug 27, 2020 | Case Studies

Best Practices: Engaging Primary Care Physicians and Specialists in Multidisciplinary Opinions and Tumor Board Conferences

Aug 17, 2020 | Blog

OncoLens Virtual Tumor Board and Cancer Conference Security – Letter from CEO

Jun 22, 2020 | News and Events

Breast Cancer Surgical Space Adapts in Response to COVID-19 Crisis, Prepares for Lockdowns to Lift

Jun 22, 2020 | News and Events

OncoLens Webinar Series: Learn How to Recoup Lost Revenue for Your Cancer Center

May 20, 2020 | News and Events

How to Use Telehealth in Cancer Care During the Coronavirus Pandemic And Beyond

Mar 02, 2020 | Case Studies

MaineGeneral Medical Decreases Tumor Board Conference Prep Time by 90%

Feb 24, 2020 | News and Events

Project ECHO® Learning Series

3,000,000+

85-90%

250,000+

OncoLens Resources

NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients

Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result

NSCLC Patient and Adjuvant Chemotherapy

Patient with Possible Synchronous Early-stage NSCLC and Different DetermaRx Results

Patient with NSCLC Who Recurred within a Year

Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion

Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy

Fast-Growing Oncology Startup OncoLens Secures $7.25 Million Series A Funding

Best Practices: Building the Future of Multidisciplinary Cancer Care

MTC: Patient with Stomach Cancer and KIT exon 11 and ATM Mutations

Patient with Prostate Cancer and CDK12 and TP53 Mutations

MTB Discussion for Patients with KIT and CDK12 Mutations

Karmanos Cancer Institute to Implement OncoLens Multidisciplinary Cancer Treatment Planning Software Solution

Four Factors Affecting the Post-COVID Cancer Care Landscape

Best Practices: Engaging Primary Care Physicians and Specialists in Multidisciplinary Opinions and Tumor Board Conferences

OncoLens Virtual Tumor Board and Cancer Conference Security – Letter from CEO

Breast Cancer Surgical Space Adapts in Response to COVID-19 Crisis, Prepares for Lockdowns to Lift

OncoLens Webinar Series: Learn How to Recoup Lost Revenue for Your Cancer Center

How to Use Telehealth in Cancer Care During the Coronavirus Pandemic And Beyond

MaineGeneral Medical Decreases Tumor Board Conference Prep Time by 90%

Oncology Start-up OncoLens Named to Top 10 List of Innovative Technology Companies in Georgia